Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies (ADPT) to Buy from Neutral with a $9 price target Since October 2024, ...

The third among the 10 stocks insiders are getting rid of in March is a commercial-stage biotech, Adaptive Biotechnologies ...

The successful go-live of Neospin™ delivers a modern pension administration system with enhanced capabilities for North Dakota's Teachers' Fund for Retirement ...

Adaptive Biotechnologies (ADPT) has launched an upgraded version of its clonoSEQ assay for measurable residual disease detection in diffuse ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ ...

Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS ...

In part 2 of this interview with Frederick L. Locke, MD, lead investigator on the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials of allogeneic chimeric antigen receptor T-cell therapy ...

Staying up to date with data from trials and information from organizations dedicated to cancer research is crucial for oncology nurses and APPs. An oncology nurse recommends that remaining aware of ...

“The PRECISE-HL trial represents a significant milestone in our pursuit of using MRD to personalise therapy for patients.

Foresight Diagnostics, which provides ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of the PRECISE-HL clinical trial with the University of Washington ...

End of therapy ctDNA-MRD analysis will also be an exploratory endpoint for the trial. For more information about the PRECISE-HL study, including eligibility and detailed protocol, please visit the ...